Published in J Am Coll Cardiol on April 01, 1992
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest (1949) 8.50
Thrombolytic therapy: current status (1). N Engl J Med (1988) 5.44
Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol (1982) 4.08
Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell (1986) 2.85
THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest (1939) 2.43
Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA (1992) 2.27
Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol (1984) 2.13
High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem (1969) 2.09
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
NF-kappa B-dependent inhibition of apoptosis is essential for host cellsurvival during Rickettsia rickettsii infection. Proc Natl Acad Sci U S A (1998) 1.92
Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem (1983) 1.77
Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest (1985) 1.76
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol (2012) 1.60
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol (1974) 1.51
Thrombolytic therapy: current status (2). N Engl J Med (1988) 1.49
Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol (2000) 1.47
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med (1971) 1.41
Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest (1992) 1.41
Acquired "storage pool disease" of platelets associated with circulating antiplatelet antibodies. Am J Med (1974) 1.40
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol (1990) 1.39
Thrombogenic factors and recurrent coronary events. Circulation (1999) 1.38
Unusual anemias. Am J Hematol (1997) 1.38
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol (1986) 1.34
The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta (1986) 1.31
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis (1977) 1.31
THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest (1940) 1.30
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem (1969) 1.28
Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci (1965) 1.27
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg (1994) 1.26
Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med (1977) 1.26
von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood (1987) 1.25
Fibrinolysis. Annu Rev Med (1968) 1.20
Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood (1980) 1.18
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Ann Intern Med (1986) 1.17
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am (1997) 1.16
The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med (1979) 1.14
Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A (1987) 1.10
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost (1985) 1.10
Structural studies of the functional heterogeneity of von Willebrand protein polymers. Blood (1981) 1.10
Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation. Infect Immun (1996) 1.10
Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc Natl Acad Sci U S A (1990) 1.09
Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation. Infect Immun (1997) 1.09
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. Circulation (1985) 1.08
E-selectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells. Blood (1993) 1.08
Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood (1987) 1.08
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol (1992) 1.07
Von Willebrand protein binds to extracellular matrices independently of collagen. Proc Natl Acad Sci U S A (1984) 1.07
Rickettsia rickettsii infection of cultured endothelial cells induces release of large von Willebrand factor multimers from Weibel-Palade bodies. Blood (1991) 1.07
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost (2005) 1.06
Chronic intravascular coagulation syndrome. N Engl J Med (1968) 1.06
Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. J Biol Chem (1974) 1.05
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA (1983) 1.05
Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost (1994) 1.04
Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain. Proc Natl Acad Sci U S A (1982) 1.04
Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J (1992) 1.03
Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow-up studies. Am J Cardiol (1984) 1.03
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med (1983) 1.02
Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood (1980) 1.02
Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol (1993) 1.01
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol (1989) 1.00
Nightmares and trauma: a comparison of nightmares after combat with lifelong nightmares in veterans. Am J Psychiatry (1984) 0.99
Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med (1992) 0.99
DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost (1996) 0.98
High molecular weight derivatives of human fibrinogen produced by plasmin. 3. Their NH2-terminal amino acids and comparison with the "NH2-terminal disulfide knot". J Biol Chem (1972) 0.98
Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood (1986) 0.98
Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med (1975) 0.98
Comparative effects of fibrinogen degradation fragments D and E on coagulation. Br J Haematol (1972) 0.97
Rickettsia rickettsii infection of cultured human endothelial cells induces tissue factor expression. Blood (1994) 0.96
Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood (1988) 0.96
Coronary thrombolysis for evolving myocardial infarction. Drugs (1984) 0.96
Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J Clin Invest (1968) 0.95
Effects of fibrinogen degradation products on platelets and coagulation. Thromb Diath Haemorrh Suppl (1966) 0.95
The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage. Trans Assoc Am Physicians (1967) 0.94
Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood (1984) 0.94
Identification and purification of fibrinogen degradation products produced by plasmin: considerations on the structure of fibrinogen. Scand J Haematol Suppl (1971) 0.93
Tissue plasminogen activator (t-PA). Will it fulfill its promise? N Engl J Med (1985) 0.92
Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen (Paris I). Nature (1974) 0.92
Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost (2009) 0.92
One-year follow-up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura. Transfusion (1981) 0.92
Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB. Infect Immun (1998) 0.92
A simple technique for the measurement of plasma heparin concentration during anticoagulant therapy. Thromb Diath Haemorrh (1970) 0.91
Recombinant streptokinase: opportunity for an improved agent. Blood Coagul Fibrinolysis (1993) 0.91
Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem (1980) 0.91
Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers. J Cell Biol (1985) 0.91
Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol (1996) 0.91
Lower risk of thromboembolic disease after total hip replacement with non-cemented than with cemented prostheses. Lancet (1986) 0.90
Concepts of clot lysis. Annu Rev Med (1986) 0.89
Proteasome-independent activation of nuclear factor kappaB in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsii. Infect Immun (1998) 0.89
Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res (1994) 0.89
Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. J Biol Chem (1993) 0.88